Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

By afschroeder • September 22, 2025

Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576-4. Epub ahead of print. PMID: 40976249.

Tags: Dermatology, Publications

Ethical Considerations of Excusing Students With Alopecia Areata From Physical Education Activities

Taghizadeh CS, Goh C, Lipner SR. Ethical Considerations of Excusing Students With Alopecia Areata From Physical Education Activities. J Am Acad Dermatol. 2026 Mar 20:S0190-9622(26)00455-X.[...]

US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European Academy of Dermatology and Venereology

Kasperkiewicz M, Thapa M, Adotama P, Tomayko MM, Culton DA. US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European[...]

Single-cell and spatial profiling reveal cDC2A-CXCL13+CD8+ T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planus

Jiang R, Bogle R, Xing X, Kirma J, Fox J, Harms PW, Do T, Billi AC, Kahlenberg JM, Modlin RL, Teles R, West J, Mangold[...]